| Theme | New Drugs for Dialysis Patients | |
|---|---|---|
| Title | New agents for prostate cancer treatment | |
| Publish Date | 2006/06 | |
| Author | Fumio Tsukuda | Department of Urology, Kagawa University, Faculty of Medecine |
| Author | Yoshiyuki Kakehi | Department of Urology, Kagawa University, Faculty of Medecine |
| [ Summary ] | Androgen deprivation is a first-line chemotherapy for prostate cancer. In most men, prostate cancer ultimately progresses to an androgen-independent state, resulting in death due to widespread metastasis. We examined several new agents for hormone-refractory prostate cancer. They are docetaxel, suramin, bisphosphonate and an angiotensin II receptor blocker. Each drug has uinque characteristics and different mechanisms related to cytotoxicity for prostate cancer. These drugs will extend hormone-refractory prostate cancer patients' survival rates and will also be available for dialysis patients. |
|